-
Track & Monitor
Venture Capital Investment Trends in Pharma - Q2 2026
This report analyzes the venture capital (VC) investment activity in Q2 2026 in the Pharma sector.
-
Sector Analysis
Emerging Market Outsourcing Report, Q2 2026
Report Value Proposition – Why Does Pharma Outsourcing Matter? Pharmaceutical outsourcing continues to play a critical role in helping drug manufacturers improve efficiency, reduce costs, and accelerate product development. As emerging markets expand their manufacturing capabilities, contract manufacturing organizations (CMOs) are becoming increasingly important partners across active pharmaceutical ingredient (API) production, biologics, drug formulation, packaging, and commercial manufacturing. GlobalData's Emerging Pharma Market Outsourcing report provides a comprehensive analysis of pharmaceutical manufacturing trends across emerging markets, with a particular focus on...
-
Sector Analysis
Focal Segmental Glomerulosclerosis (FSGS): Market View, Current and Future Competitive Landscape
Why Does the FSGS Therapeutics Market Matter? Focal Segmental Glomerulosclerosis (FSGS) is a rare kidney disease characterized by scarring of the glomeruli and can lead to progressive kidney dysfunction. The treatment landscape is undergoing a significant shift as disease-specific therapies emerge alongside established supportive and off-label treatment approaches. GlobalData’s Focal Segmental Glomerulosclerosis (FSGS): Market View provides a data-driven assessment of the current and future competitive landscape, combining Pharma Intelligence Center data with in-house analyst expertise. In 2025, there were 37,049...
-
Consumer Insights
Industry Insights: How Dietary Supplements Have Evolved Beyond Traditional Health Management
This report highlights the shift in consumer preferences from traditional health supplements to modern formats designed to address specific health needs. As people become more health-conscious, they are increasingly seeking tailored, localized products that support longevity and overall vitality. Growing interest in these contemporary supplements is largely fueled by online marketing and easier access to health information through social media. The report explores consumer interest in nootropics, nutricosmetics, and cellular health supplements. As health and wellness become a higher priority...
-
Sector Analysis
IgA Nephropathy (Berger’s Disease): Market View, Current and Future Competitive Landscape
This report provides a data-driven overview of the current and future competitive landscape in IgA Nephropathy (Berger’s Disease) Therapeutics. • In 2025, there were 102,155 incident cases of Berger's disease in the 16 countries covered in GlobalData’s epidemiology forecast. • Berger's disease is primarily managed with blood pressure medication like ACE inhibitors or ARBs to protect the kidneys. For high-risk patients, corticosteroids and newer targeted therapies are also available to slow the disease's progression. • The Berger's disease pipeline holds...
-
Sector Analysis
Postpartum Depression (PPD): Market View, Current and Future Competitive Landscape
This report provides a data-driven overview of the current and future competitive landscape in Postpartum Depression (PPD) Therapeutics. In 2025, there were 10.89 million prevalent cases of PPD across the 16 countries covered in GlobalData’s epidemiology forecast. PPD is typically managed with psychotherapy (CBT or interpersonal therapy) and antidepressants, most commonly SSRIs, tailored to breastfeeding considerations and patient preferences, alongside practical supports such as sleep and family assistance. For moderate-to-severe illness, faster-acting neuroactive steroid treatments include IV brexanolone (a 60-hour...
-
Sector Analysis
Reflux Esophagitis (Gastroesophageal Reflux Disease): Market View, Current and Future Competitive Landscape
Why Does the Global Reflux Esophagitis Therapeutics Market Matter? Reflux esophagitis and gastroesophageal reflux disease (GERD) represent a significant global therapeutic market, with treatment typically involving lifestyle modifications, pharmacological therapies, and, in selected cases, surgical or endoscopic interventions. GlobalData’s Reflux Esophagitis (Gastroesophageal Reflux Disease) Therapeutics Market View provides a data-driven assessment of the current and future competitive landscape, combining Pharma Intelligence Center data with analyst expertise. In 2025, there were 308.98 million 12-month total diagnosed prevalent cases of GERD across...
-
Sector Analysis
Hepatocellular Carcinoma (HCC): Epidemiology Report and Forecast to 2035
Hepatocellular carcinoma (HCC) arises from the hepatocyte cells in the liver and is the most common primary liver cancer, accounting for approximately 90% of all primary cancers of the liver (Asafo-Agyei and Samant, 2023). HCC has a high mortality rate and is the third leading cause of cancer deaths annually worldwide (Singal, Kanwal and Llovet, 2023). Major risk factors for HCC include infection with the hepatitis B virus (HBV), infection with the hepatitis C virus (HCV), and high alcohol consumption...
-
Sector Analysis
Hepatitis C Virus: Epidemiology Report and Forecast to 2035
Hepatitis C is an inflammatory liver disease caused by the hepatitis C virus (HCV). HCV primarily spreads through direct blood contact, which can happen via needle/syringe sharing in people who inject drugs, unscreened blood transfusions and unsterilized medical equipment, and sexual contact involving blood. Additionally, vertical transmission of HCV can occur (Public Health England, 2018). Many people with hepatitis C are asymptomatic and unaware that they have the infection, with only approximately a quarter of patients exhibiting symptoms, including fatigue,...